| In Vitro |
ODN 2088 (0.01, 0.1, 1, 10 μM; 48 h) shows no cytotoxic for for human PBMCs[1]. ODN 2088 (0.01, 0.1, 1, 10 μM; 24 h) inhibits the release of IFN-α in CpG-ODN 2216 (3 μM) and TLR7-ligand RNA-ORN 22075 (5 μM) stimulated human PBMCs[1]. ODN 2088 (0.01, 0.1, 1, 10 μM; 48 h) hardly inhibits the IL-6 release stimulated with CpG-ODN 2006 (100 nM) but inhibits the IL-6 release stimulated with imiquimod (5 μg/ml) in human PBMCs[1]. ODN 2088 (0.1, 1, 10 μM; 24 h) hardly inhibits IL-6 release by B-cells stimulated with CpG-DNA 2006 (100 nM) but inhibits the IL-6 release by imiquimod (5 μg/ml) stimulated human B-cells[1]. ODN 2088 (1, 10 μM; 48 h) increases the expression of CD86 and HLA-DR in the absence of CpG-ODN 2006 or imiquimod in CD20+ B-cells[1]. ODN 2088 presumably impairs TLR9-induced signaling induces by CpG-ODNs by competitive binding to the C-terminal fragment of TLR9[1]. ODN 2088 (0.001, 0.01, 0.1, 1, 10 μM; 24 h) inhibits the TNF-α secretion in a dose-dependent manner in CpG-ODN 1826 (100 nM) stimulated BMDMs and shows weekly inhibits when stimulated by the TLR7-agonist imiquimod[3]. ODN 2088 (10 μM) stimulates B cells to proliferate[3]. Cell Cytotoxicity Assay[1] Cell Line: Human PBMCs Concentration: 0.01, 0.1, 1, 10 μM Incubation Time: 48 h Result: Showed no cytotoxic for for human PBMCs.
|
